Sirtex Medical Limited (SRX.AX)


ASX - ASX Delayed Price. Currency in AUD
33.53+0.14 (+0.42%)
At close: 2:11 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open33.60
Prev Close33.39
Bid34.01 x
Ask32.55 x
Day's Range32.82 - 33.60
52wk Range25.10 - 41.33
1y Target EstN/A
Market Cap1.93B
P/E Ratio (ttm)36.37
BetaN/A
Volume293,360
Avg Vol (3m)409,107
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Sirtex Medical Ltd. :SRX-AU: Earnings Analysis: For the six months ended June 30, 2016 : August 31, 2016
    Capital Cube16 hours ago

    Sirtex Medical Ltd. :SRX-AU: Earnings Analysis: For the six months ended June 30, 2016 : August 31, 2016

    Categories: Yahoo Finance Get free summary analysis Sirtex Medical Ltd. reports financial results for the half-year ended June 30, 2016. Highlights Summary numbers: Revenues of AUD 119.90 million, Net Earnings of AUD 27.64 million. Gross margins widened from 84.25% to 84.71% compared to the same period last year, operating (EBITDA) margins now 32.33% from 30.08%. Earnings growth from ... Read more (Read more...)

  • Sirtex Medical Ltd.: Gathering momentum, can it sustain its performance?
    Capital Cube6 days ago

    Sirtex Medical Ltd.: Gathering momentum, can it sustain its performance?

    Categories: Yahoo Finance Sirtex Medical Ltd. relative valuation is UNDERVALUED and it has a fundamental analysis score of 86. Our analysis is based on comparing Sirtex Medical Ltd. with the following peers – Starpharma Holdings Limited, Clinuvel Pharmaceuticals Limited and Alchemia Limited (SPL-AU, CUV-AU and ACL-AU). Sirtex Medical Ltd. has shown excellent performance overall, both over the last ... Read more (Read more...)

  • Business Wire6 days ago

    Sirtex Medical Inc. Announces 19 Percent Dose Sales Growth of SIR-Spheres® Y-90 resin microspheres in Fiscal Year 2016

    Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited , a leading manufacturer of targeted liver cancer therapies, today announced dose sales of SIR-Spheres® Y-90 resin microspheres grew 19 percent in the Americas region for the fiscal year ending June 30, 2016, compared to the previous corresponding period.